Ribose-Nucleic Acid (RNA)-based Therapeutics Market Report 2024

Where is the largest and fastest growing market for ribose-nucleic acid (RNA)-based therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The ribose-nucleic acid (RNA)-based therapeutics market size has grown strongly in recent years. It will grow from $14.54 billion in 2023 to $15.79 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The increase during the historic period can be attributed to several factors, including rising investments and funding, the breakthrough discovery of RNA interference (RNAi), the clinical success of antisense oligonucleotides (ASOs), supportive regulatory frameworks, and various collaborations and partnerships.

The ribose-nucleic acid (RNA)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.3 billion in 2028 at a compound annual growth rate (CAGR) of 9%. The anticipated growth in the forecast period is driven by the broadening of indications, increased market demand and adoption, supportive regulatory measures, the integration of AI and machine learning, and new applications in rare diseases. Key trends for the forecast period include the development of advanced delivery systems, multi-target RNA therapeutics, personalized RNA therapies, regulatory progress, and overall commercialization and market expansion.

The rising incidence of cancer is anticipated to drive the growth of the ribonucleic acid (RNA)-based therapeutics market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, can be fatal if not treated. Factors contributing to the increasing cancer prevalence include an aging population, lifestyle changes, greater exposure to risk factors, and improved detection techniques. RNA-based therapeutics present a promising treatment option by targeting the genetic and molecular mechanisms involved in cancer. For example, data from the Australian Institute of Health and Welfare reveals that approximately 151,000 people were diagnosed with cancer in 2021 (excluding basal cell and squamous cell skin cancers), with numbers expected to reach 185,000 by 2030. This rising prevalence is driving the RNA-based therapeutics market.

Leading companies in the RNA-based therapeutics market are concentrating on developing novel medication solutions, including messenger RNA (mRNA)-based booster vaccines. These vaccines aim to improve immunization effectiveness, address new viral variants, and enhance the durability of vaccine-induced immunity. An mRNA-based booster vaccine prompts cells to produce a protein that strengthens the immune response against a specific pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an Indian pharmaceutical firm, introduced GEMCOVAC-OM, India's first mRNA booster vaccine targeting the Omicron variant of COVID-19. This booster is crucial due to the limited efficacy of earlier vaccines against Omicron, with GEMCOVAC-OM utilizing mRNA technology to enhance immunity and provide better protection against the evolving virus.

In May 2024, Orna Therapeutics, a US-based biotech firm specializing in RNA-based therapeutics, acquired ReNAgade Therapeutics for an undisclosed sum. This acquisition aims to strengthen Orna's position in the industry by integrating its circular RNA expression technology with ReNAgade's advanced lipid nanoparticle (LNP)-based RNA delivery systems and editing programs. ReNAgade Therapeutics, also based in the US, focuses on RNA-based therapeutic solutions.

Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics.

North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2023. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

RNA-based therapeutics are a category of medical treatments that use ribonucleic acid (RNA) molecules to affect cellular functions, often by targeting specific genetic sequences. These therapies aim to address a range of conditions, such as genetic disorders, cancers, and infectious diseases, by altering gene expression, protein production, or cellular signaling pathways.

The primary types of RNA-based therapeutics are RNA interference (RNAi) and RNA antisense. RNA interference (RNAi) is a natural process where RNA molecules suppress gene expression or translation by targeting and neutralizing specific mRNA molecules. These technologies are employed across various therapeutic areas, including oncology, genetic disorders, ophthalmology, hematological disorders, and acute hepatic porphyria (AHP). They are utilized by different users, such as research institutions, hospitals, and clinics.

The ribose-nucleic acid (RNA)-based therapeutics market research report is one of a series of new reports that provides ribose-nucleic acid (RNA)-based therapeutics market statistics, including ribose-nucleic acid (RNA)-based therapeutics industry global market size, regional shares, competitors with a ribose-nucleic acid (RNA)-based therapeutics market share, detailed ribose-nucleic acid (RNA)-based therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the ribose-nucleic acid (RNA)-based therapeutics industry. This ribose-nucleic acid (RNA)-based therapeutics market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ribose-nucleic acid (RNA)-based therapeutics market consists of revenues earned by entities by custom synthesis of RNA, RNA delivery systems, and RNA sequencing analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribose-nucleic acid (RNA)-based therapeutics market also include the sale of microRNA (miRNA) therapeutics, antisense oligonucleotides, and messenger RNA (mRNA) vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.